Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > バイオシミラー

Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO) (HV974026)

Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)
価格(USD):
スペック:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

  • SDS

概要
カタログ番号HV974026
説明
Durvalumab (HV974026) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Resources
種反応性Human
アプリケーションELISA, Bioactivity: FCM, Functional assay, Research in vivo
宿主種Human
クローン性Monoclonal
アイソタイプIgG1-kappa
テスト済みアプリケーション WB, FCM
ターゲット B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1
エンドトキシンレベル < 10 EU/mg
純度 >95% as determined by SDS-PAGE.
精製 Protein A/G purified from cell culture supernatant.
アクセッション番号 Q9NZQ7
形態 Liquid
保存バッファー 0.01M PBS pH 7.4.

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

安定性と保存 Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名MEDI4736, 1428935-60-7
背景

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

_x005F_x000D_ _x005F_x000D_
1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443
_x005F_x000D_ _x005F_x000D_
2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410
_x005F_x000D_ _x005F_x000D_
3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417
_x005F_x000D_ _x005F_x000D_
4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419
_x005F_x000D_ _x005F_x000D_
5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298
_x005F_x000D_ _x005F_x000D_
6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077
_x005F_x000D_ _x005F_x000D_
7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201
_x005F_x000D_
注意事項 For research use only. Not suitable for clinical or therapeutic use.
イメージ
  • Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)

    SEC-HPLC

    SEC-HPLC detection for Research Grade Durvalumab.

  • Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)

    Bioactivity

    Detects Human CD274/PD-L1/B7-H1 in indirect ELISAs.

  • Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)

    Flow Cytometry

    Flow-cytometry using anti-human CD274 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human CD274 monoclonal antibody (Catalog HV974036) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.

  • Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Durvalumab

  • Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)

    Flow CytoMetry

    Flow-cytometry using FITC anti-human CD274 antibody. MDA-MB-231 cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD274 monoclonal antibody (Catalog: HV974026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

  • Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)

    Flow CytoMetry

    Flow-cytometry using APC anti-human CD274 antibody. MDA-MB-231 cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD274 monoclonal antibody (Catalog: HV974026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

  • Anti-Human PD-L1 Reference Antibody (Durvalumab, RUO)

    Western blot

    Western blot analysis was performed using anti-CD5 monoclonal antibody at 1μg/ml on various samples.
    Lane 1: recombinant human CD5 (Catalog No: HY046011), 50ng
    Lane 2: recombinant human CD5 (Catalog No: HY046011), 30ng
    Lane 3: recombinant human CD5 (Catalog No: HY046011), 20ng
    Lane 4: recombinant human CD5 (Catalog No: HY046011), 10ng

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: [email protected]

ディストリビューターリスト